HR+/HER2- Metastatic Breast Cancer: key endpoint results by drug

The key endpoints of HR+/HER2- Metastatic Breast Cancer trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the HR+/HER2- Metastatic Breast Cancer page.

PFS, median

PFS, median in HR+/HER2- Metastatic Breast Cancer: 37 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Abemaciclib16.49.3+7.1n 446NCT02107703 Phase 3, primary
Alpelisib (BYL719)115.7+5.3n 169NCT02437318 Phase 3, primary
Atezolizumab8.26.8+1.4n 133NCT02924883 Phase 2, primary
Bevacizumab8.78+0.7n 248NCT00333775 Phase 3, primary
Capecitabine5.55.4±0n 266NCT01234337 Phase 3, primary
Capivasertib7.23.6+3.6n 355NCT04305496 Phase 3, primary
Chidamide7.4a3.8+3.6—NCT02482753 Phase 3, primary
Culmerciclib16.6a7.5+9.1—NCT05375461 Phase 3, primary
Datopotamab Deruxtecan6.94.9 (Investigator's Choice of Chemotherapy (ICC))—n 365NCT05104866 Phase 3, primary
Docetaxel9.58.2+1.3n 759NCT00703326 Phase 3, primary
Elacestrant3.81.9 (Standard of Care (SoC))—n 115NCT03778931 Phase 3, primary
Eribulin mesylate4.14.2 (Capecitabine)—1.4 mg/m^2 · n 554NCT00337103 Phase 3, primary
Everolimus6.92.8+4.1n 485NCT00863655 Phase 3, primary
Exemestane7.310 (Capecitabine)—n 153NCT02028507 Phase 3, primary
Fulvestrant4.73.8+0.9n 146NCT00390455 Phase 3, primary
Gemcitabine8.99.0 (Gemcitabine Plus Docetaxel)—n 236NCT00191152 Phase 3, secondary
Imlunestrant5.55.5 (Investigator's Choice of Endocrine Therapy)—n 331NCT04975308 Phase 3, primary
Inavolisib157.3+7.7n 161NCT04191499 Phase 2/3, primary
metformin5.46.3−0.9n 22NCT01310231 Phase 2, primary
Nab-paclitaxel9.311.0 (Paclitaxel)—n 267NCT00785291 Phase 3, primary
Neratinib12.912.9 (Trastuzumab + Paclitaxel)—n 242NCT00915018 Phase 2, primary
Olaparib74.2 (Chemotherapy)—300 mg bd · n 205NCT02000622 Phase 3, primary
Palbociclib24.814.5+10.3n 444NCT01740427 Phase 3, primary
Pembrolizumab2.12.6 (Carboplatin)—wk 18 · n 51NCT03095352 Phase 2, primary
Pertuzumab14.113.7 (Trastuzumab + Taxane)—n 367NCT01120184 Phase 3, primary
Ribociclib20.512.8+7.7n 484NCT02422615 Phase 3, primary
Sacituzumab Govitecan5.54 (Treatment of Physician's Choice)—n 272NCT03901339 Phase 3, primary
Talazoparib8.65.6 (Physician's Choice Treatment)—n 287NCT01945775 Phase 3, primary
Trastuzumab Emtansine14.113.7 (Trastuzumab + Taxane)—n 367NCT01120184 Phase 3, primary
Vepdegestrant3.73.6 (Fulvestrant)—n 313NCT05654623 Phase 3, primary
Alisertib5.6b——n 46NCT02860000 Phase 2, secondary
Apatinib4.9b——n 26NCT02878057 Phase 2, primary
Durvalumab2.5b——1 mg/kg durvalumab + 3 mg/kg tremelimumab · n 10NCT01975831 Phase 1, secondary
Enfortumab Vedotin5.4b——n 45NCT04225117 Phase 2, secondary
Gefitinib26.5b——n 14NCT00357734 Phase 3, secondary
Goserelin21.8b——n 307NCT03096847 Phase 3, secondary
Patritumab Deruxtecan7.2b——n 60NCT04699630 Phase 2, secondary

Drugs checked with no result here: 51 not reported, 36 trial running.

OS, median

OS, median in HR+/HER2- Metastatic Breast Cancer: 29 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Abemaciclib45.837.3+8.5n 446NCT02107703 Phase 3, secondary
Alpelisib (BYL719)39.331.4+7.9n 169NCT02437318 Phase 3, secondary
Atezolizumab26.526.0 (Fulvestrant)—n 30NCT03280563 Phase 1/2, secondary
Bevacizumab28.825.8+3n 239NCT01663727 Phase 3, secondary
Capecitabine16.415.6 (Capecitabine)—n 609NCT00082433 Phase 3, primary
Capivasertib32.8——n 54NCT01625286 Phase 1/2, secondary
Datopotamab Deruxtecan18.618.3 (Investigator's Choice of Chemotherapy (ICC))—n 365NCT05104866 Phase 3, primary
Docetaxel30.328.7+1.6n 759NCT00703326 Phase 3, secondary
Eribulin mesylate15.914.5 (Capecitabine)—1.4 mg/m^2 · n 554NCT00337103 Phase 3, primary
Everolimus31.026.6+4.4n 485NCT00863655 Phase 3, secondary
Exemestane33.732 (Capecitabine)—n 206NCT02028507 Phase 3, secondary
Fulvestrant29.926.4+3.5n 146NCT00390455 Phase 3, secondary
Gemcitabine23.323.0 (Gemcitabine Plus Docetaxel)—n 236NCT00191152 Phase 3, secondary
Nab-paclitaxel23.526.6 (Paclitaxel)—n 267NCT00785291 Phase 3, secondary
Neratinib19.723.6 (Lapatinib+Capecitabine)—n 117NCT00777101 Phase 2, secondary
Olaparib19.319.6 (Chemotherapy)—300 mg bd · n 205NCT02000622 Phase 3, secondary
Palbociclib53.951.2+2.7n 444NCT01740427 Phase 3, secondary
Pembrolizumab13.412.5 (Eribulin Mesylate)—n 44NCT03051659 Phase 2, secondary
Pertuzumab53.750.9 (Trastuzumab + Taxane)—n 367NCT01120184 Phase 3, secondary
Ribociclib63.951.4+12.5n 334NCT01958021 Phase 3, secondary
Sacituzumab Govitecan14.511.2 (Treatment of Physician's Choice)—n 272NCT03901339 Phase 3, secondary
Talazoparib19.319.5 (Physician's Choice Treatment)—n 287NCT01945775 Phase 3, secondary
Trastuzumab Emtansine53.750.9 (Trastuzumab + Taxane)—n 367NCT01120184 Phase 3, secondary
Zoledronic acid26.932.1 (Zoledronic Acid)—n 124NCT00365105 Phase 3, secondary
Apatinib18b——n 26NCT02878057 Phase 2, primary
Durvalumab19.4b——1 mg/kg durvalumab + 3 mg/kg tremelimumab · n 10NCT01975831 Phase 1, secondary
Gefitinib23.5b——n 14NCT00357734 Phase 3, secondary
Goserelin27.3b——n 119NCT03056755 Phase 2, secondary
Methotrexate8.2b——n 3NCT00992602 Phase 2, secondary

Drugs checked with no result here: 51 not reported, 42 trial running, 2 not posted.

ORR

ORR in HR+/HER2- Metastatic Breast Cancer: 28 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Abemaciclib35.2%16.1%+19.1n 446NCT02107703 Phase 3, secondary
Alpelisib (BYL719)26.6%13.4%+13.2n 169NCT02437318 Phase 3, secondary
Atezolizumab10%10% (Fulvestrant)—n 30NCT03280563 Phase 1/2, primary
Axitinib41.1%23.6% (Docetaxel + Placebo)—n 112NCT00076024 Phase 1/2, secondary
Bevacizumab54%33.2%+20.8n 202NCT01663727 Phase 3, secondary
Capecitabine22.9%17.9% (Capecitabine)—n 384NCT01095003 Phase 3, secondary
Docetaxel44.7%37.9%+6.8n 759NCT00703326 Phase 3, secondary
Eribulin mesylate11%11.5% (Capecitabine)—1.4 mg/m^2 · n 554NCT00337103 Phase 3, secondary
Everolimus9.5%0.4%+9.1n 485NCT00863655 Phase 3, secondary
Fulvestrant20%9%+11n 101NCT00390455 Phase 3, secondary
Gemcitabine19.8%12.7%+7.1n 81NCT00493636 Phase 2, secondary
Imlunestrant10.3%6.4% (Investigator's Choice of Endocrine Therapy)—n 331NCT04975308 Phase 3, secondary
Nab-paclitaxel34.1%38.2% (Paclitaxel)—n 267NCT00785291 Phase 3, secondary
Palbociclib46.4%38.3%+8.1n 444NCT01740427 Phase 3, secondary
Pembrolizumab8%12.5% (Carboplatin)—wk 18 · n 51NCT03095352 Phase 2, secondary
Pertuzumab88.6%78.2%+10.4wk 13 · n 219NCT02586025 Phase 3, secondary
Ribociclib32.4%21.5%+10.9n 484NCT02422615 Phase 3, secondary
Talazoparib62.6%27.2% (Physician's Choice Treatment)—n 219NCT01945775 Phase 3, secondary
Trastuzumab Emtansine59.7%67.9% (Trastuzumab + Taxane)—n 303NCT01120184 Phase 3, secondary
Vepdegestrant10.9%3.6% (Fulvestrant)—n 221NCT05654623 Phase 3, secondary
Alisertib19.6%b——n 46NCT02860000 Phase 2, primary
Enfortumab Vedotin39%b——n 41NCT04225117 Phase 2, primary
Exemestane14.3%b——wk 48 · n 49NCT01743560 Phase 4, primary
Goserelin29.3%b——n 3246NCT02941926 Phase 3, secondary
Neratinib35.9%b——240 mg + 25 mg/m² · n 64NCT00706030 Phase 1/2, primary
Olaparib49.6%b——n 252NCT03286842 Phase 3, secondary
Patritumab Deruxtecan35%b——n 60NCT04699630 Phase 2, primary
Pazopanib0%b——wk 156 · n 8NCT01498458 Phase 1, secondary

Drugs checked with no result here: 51 not reported, 43 trial running, 2 not posted.

Clinical benefit rate

Clinical benefit rate in HR+/HER2- Metastatic Breast Cancer: 21 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Abemaciclib72.2%56.1%+16.1n 446NCT02107703 Phase 3, secondary
Alpelisib (BYL719)61.5%44.8%+16.7n 169NCT02437318 Phase 3, secondary
Atezolizumab26.7%15% (Fulvestrant)—n 30NCT03280563 Phase 1/2, secondary
Capecitabine59%53% (Capecitabine)—10 mg + 25 mg · n 104NCT01783444 Phase 2, secondary
Docetaxel60.4%62% (Trastuzumab)—n 326NCT00667251 Phase 3, secondary
Everolimus33.4%18%+15.4n 485NCT00863655 Phase 3, secondary
Fulvestrant78.3%74.1% (Anastrozole)—500 mg · n 230NCT01602380 Phase 3, secondary
Imlunestrant46.8%45.5% (Investigator's Choice of Endocrine Therapy)—n 331NCT04975308 Phase 3, secondary
Neratinib88.4%85.2% (Trastuzumab + Paclitaxel)—n 242NCT00915018 Phase 2, secondary
Palbociclib85.8%71.2%+14.6n 444NCT01740427 Phase 3, secondary
Ribociclib70.2%62.8%+7.4n 484NCT02422615 Phase 3, secondary
Vepdegestrant34.3%28.7% (Fulvestrant)—n 274NCT05654623 Phase 3, secondary
Alisertib41.3%b——wk 24 · n 46NCT02860000 Phase 2, secondary
Eribulin mesylate57.1%b——1.4 mg/m^2 · n 42NCT01323530 Phase 1/2, secondary
Exemestane48.2%b——n 199NCT03176238 Phase 3, secondary
Goserelin70.7%b——n 3246NCT02941926 Phase 3, secondary
Nab-paclitaxel86.2%b——n 1198NCT01572038 Phase 3, secondary
Patritumab Deruxtecan48.3%b——n 60NCT04699630 Phase 2, secondary
Pazopanib25%b——wk 156 · n 8NCT01498458 Phase 1, secondary
Pembrolizumab50%b——n 10NCT02648477 Phase 2, secondary
Pertuzumab86.2%b——n 1198NCT01572038 Phase 3, secondary

Drugs checked with no result here: 55 not reported, 44 trial running, 4 not posted.

  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  3. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  4. Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 124 approved or late-stage drugs with a featured trial in HR+/HER2- Metastatic Breast Cancer were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.